Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked faithfully but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my last few shares. My 1st CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire interview that I came away with a bad viewpoint of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, though the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the technology as well as connected intellectual property from Progenics to CytoDyn, as well as roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) along with the first new drug program endorsement ($five million), and also royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it has this individual remedy and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several illness types, multiple publications in addition to multiple presentations.

Might all of it be smoke cigarettes and mirrors? That is a question I have been asking myself with the very start of my interest in this particular company. Judging by way of the multiples of a huge number of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a classic battleground, or some may say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *